CD33 Inhibitor - 2019 Pipeline Insight Report Featuring Affimed Therapeutics, Boehringer Ingelheim, PersonGen Biomedicine & ImmunoGen - ResearchAndMarkets.com

DUBLIN--()--The "CD 33 Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

CD 33 Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CD 33 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for CD 33 Inhibitor

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for CD 33 Inhibitor

The report assesses the active CD 33 Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the Report

  • Provides a snapshot of the therapeutics pipeline activity for CD 33 Inhibitor
  • Features the CD 33 Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of CD 33 Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across CD 33 Inhibitor

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across CD 33 Inhibitor to formulate effective R&D strategies
  • Assess challenges and opportunities that influence CD 33 Inhibitor research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for CD 33 Inhibitor
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for CD 33 Inhibitor to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Companies Mentioned

  • Affimed Therapeutics
  • Boehringer Ingelheim
  • PersonGen Biomedicine
  • ImmunoGen

Key Topics Covered

1. Report Introduction

2. CD 33 Inhibitor - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for CD 33 Inhibitor

4. Comparative Analysis

5. CD 33 Inhibitor Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. CD 33 Inhibitor Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/okryc7

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900